Sergio Cotugno , Giacomo Guido , Francesco Di Gennaro , Francesco Cavallin , Mariantonietta Pisaturo , Lorenzo Onorato , Federica Zimmerhofer , Luca Pipitò , Giuseppina De Iaco , Giuseppe Bruno , Massimo Fasano , Agostina Pontarelli , Annarita Botta , Tiziana Iacovazzi , Rossana Lattanzio , Roberta Papagni , Elda De Vita , Alberto Zolezzi , Gianfranco Panico , Raffaella Libertone , Annalisa Saracino
{"title":"意大利有症状肺结核(STB)和无症状肺结核(ATB):一项多中心回顾性研究的结果","authors":"Sergio Cotugno , Giacomo Guido , Francesco Di Gennaro , Francesco Cavallin , Mariantonietta Pisaturo , Lorenzo Onorato , Federica Zimmerhofer , Luca Pipitò , Giuseppina De Iaco , Giuseppe Bruno , Massimo Fasano , Agostina Pontarelli , Annarita Botta , Tiziana Iacovazzi , Rossana Lattanzio , Roberta Papagni , Elda De Vita , Alberto Zolezzi , Gianfranco Panico , Raffaella Libertone , Annalisa Saracino","doi":"10.1016/j.jctube.2025.100556","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Asymptomatic tuberculosis (ATB) represents a significant proportion of tuberculosis (TB) cases. This study aimed to compare ATB and symptomatic TB (STB) cases in terms of demographic and clinical characteristics, adverse events, hospital length of stay, and treatment outcomes.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study included 510 microbiologically confirmed pulmonary TB patients across ten Italian hospitals between 2018 and 2023. STB cases presented with at least one symptom such as cough, fever, chest pain, hemoptysis, dyspnea, night sweats or weight loss. ATB cases presented with no symptoms. The endpoints included adverse events, length of hospital stay, and incompleteness of the treatment.</div></div><div><h3>Results</h3><div>ATB accounted for 36.4 % of cases (184/510). STB was significantly associated with diabetes (p = 0.03), hepatitis B/C infections (p < 0.0001), and history of TB (p = 0.01). Adjusting for clinically relevant confounders, STB was associated with higher occurrence of adverse events (odds ratio 2.04, 95 % confidence interval 1.31 to 3.23; p = 0.002), more severe adverse events (odds ratio 8.07, 95 % confidence interval 2.58 to 33.34; p = 0.001) and a 24 % increase in length of hospital stay (95 % confidence interval 7 % to 47 %; p = 0.005), but was not associated with incomplete treatment (odds ratio 0.79, 95 % confidence interval 0.47 to 1.32; p = 0.37).</div></div><div><h3>Conclusions</h3><div>STB is associated with a higher burden of adverse events. ATB poses challenges for TB elimination due to its asymptomatic nature.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"41 ","pages":"Article 100556"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Symptomatic (STB) and Asymptomatic (ATB) tuberculosis in Italy: Results from a multicenter retrospective study\",\"authors\":\"Sergio Cotugno , Giacomo Guido , Francesco Di Gennaro , Francesco Cavallin , Mariantonietta Pisaturo , Lorenzo Onorato , Federica Zimmerhofer , Luca Pipitò , Giuseppina De Iaco , Giuseppe Bruno , Massimo Fasano , Agostina Pontarelli , Annarita Botta , Tiziana Iacovazzi , Rossana Lattanzio , Roberta Papagni , Elda De Vita , Alberto Zolezzi , Gianfranco Panico , Raffaella Libertone , Annalisa Saracino\",\"doi\":\"10.1016/j.jctube.2025.100556\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Asymptomatic tuberculosis (ATB) represents a significant proportion of tuberculosis (TB) cases. This study aimed to compare ATB and symptomatic TB (STB) cases in terms of demographic and clinical characteristics, adverse events, hospital length of stay, and treatment outcomes.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study included 510 microbiologically confirmed pulmonary TB patients across ten Italian hospitals between 2018 and 2023. STB cases presented with at least one symptom such as cough, fever, chest pain, hemoptysis, dyspnea, night sweats or weight loss. ATB cases presented with no symptoms. The endpoints included adverse events, length of hospital stay, and incompleteness of the treatment.</div></div><div><h3>Results</h3><div>ATB accounted for 36.4 % of cases (184/510). STB was significantly associated with diabetes (p = 0.03), hepatitis B/C infections (p < 0.0001), and history of TB (p = 0.01). Adjusting for clinically relevant confounders, STB was associated with higher occurrence of adverse events (odds ratio 2.04, 95 % confidence interval 1.31 to 3.23; p = 0.002), more severe adverse events (odds ratio 8.07, 95 % confidence interval 2.58 to 33.34; p = 0.001) and a 24 % increase in length of hospital stay (95 % confidence interval 7 % to 47 %; p = 0.005), but was not associated with incomplete treatment (odds ratio 0.79, 95 % confidence interval 0.47 to 1.32; p = 0.37).</div></div><div><h3>Conclusions</h3><div>STB is associated with a higher burden of adverse events. ATB poses challenges for TB elimination due to its asymptomatic nature.</div></div>\",\"PeriodicalId\":37942,\"journal\":{\"name\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"volume\":\"41 \",\"pages\":\"Article 100556\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-08-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405579425000476\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579425000476","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Symptomatic (STB) and Asymptomatic (ATB) tuberculosis in Italy: Results from a multicenter retrospective study
Objective
Asymptomatic tuberculosis (ATB) represents a significant proportion of tuberculosis (TB) cases. This study aimed to compare ATB and symptomatic TB (STB) cases in terms of demographic and clinical characteristics, adverse events, hospital length of stay, and treatment outcomes.
Methods
This multicenter retrospective study included 510 microbiologically confirmed pulmonary TB patients across ten Italian hospitals between 2018 and 2023. STB cases presented with at least one symptom such as cough, fever, chest pain, hemoptysis, dyspnea, night sweats or weight loss. ATB cases presented with no symptoms. The endpoints included adverse events, length of hospital stay, and incompleteness of the treatment.
Results
ATB accounted for 36.4 % of cases (184/510). STB was significantly associated with diabetes (p = 0.03), hepatitis B/C infections (p < 0.0001), and history of TB (p = 0.01). Adjusting for clinically relevant confounders, STB was associated with higher occurrence of adverse events (odds ratio 2.04, 95 % confidence interval 1.31 to 3.23; p = 0.002), more severe adverse events (odds ratio 8.07, 95 % confidence interval 2.58 to 33.34; p = 0.001) and a 24 % increase in length of hospital stay (95 % confidence interval 7 % to 47 %; p = 0.005), but was not associated with incomplete treatment (odds ratio 0.79, 95 % confidence interval 0.47 to 1.32; p = 0.37).
Conclusions
STB is associated with a higher burden of adverse events. ATB poses challenges for TB elimination due to its asymptomatic nature.
期刊介绍:
Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.